This bill would restrict pharmaceutical companies from advertising drugs directly to consumers through television, print, social media, and other channels for at least three years after a drug receives FDA approval. During that three-year period, companies could request a waiver from the Food and Drug Administration if they believe advertising would benefit public health, though the FDA would need to approve such requests. After the initial three years, the FDA could continue to prohibit or restrict advertising for drugs that show significant safety problems based on studies, adverse event reports, or other safety data. The legislation requires the FDA to update its advertising regulations within one year of the law's enactment to enforce these restrictions. The rules would apply to drugs approved by the FDA starting one year before the bill becomes law and would not affect the FDA's existing authority to regulate drug advertising in other ways.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.